Gene fault could predict ovarian cancer drug success
Faults in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to research at Newcastle University.
The study presented at the American Society for Clinical Oncology found that women with faults in a gene known as p53 were 50 per cent less likely to survive, but tended to be more likely to respond to the drug paclitaxel in addition to the standard treatment of carboplatin.
Those without such mutations had better survival rates but did not benefit from having paclitaxel added to their treatment, meaning patients like this could be spared unnecessary side effects in the future.
Dr Hilary Calvert, who led the study, said: These results show that ovarian cancer patients whose tumour had a faulty p53 gene survive longer if given paclitaxel. Although survival rates have improved dramatically in recent years, ovarian cancer remains one of the most deadly cancers in women and efforts to improve survival by targeting treatments at those most likely to benefit are urgently needed.
The work, led by researchers from Newcastle University including Professor John Lunec, the UCL Cancer Institute and the MRC, was funded by Cancer Research UK and the Medical Research Council (MRC).
The scientists examined tumour samples from 265 patients who had taken part in the MRCs ICON 3 study, which found no significant benefit in giving patients paxlitaxel in addition to the standard treatment of carboplatin.
But this contradicted earlier studies, which showed that adding paxlitaxel to treatment improved survival leading to this drug combination being adopted as a standard treatment for ovarian cancer.
The researchers believed that this difference in response to paxlitaxel could be related to the genetic makeup of the tumour and suspected that p53 faults may be behind this.
So to put their theory to the test they analysed all the tumour samples to see which had p53 faults. This revealed that p53 was inactive or faulty in around half of the samples (130/265) and also that patients only benefited from paxlitaxel if p53 was faulty in their tumour.
Dr Lesley Walker, Cancer Research UKs director of cancer information, said: Our scientists discovered p53 over thirty years ago and its good to see this now being used as a biomarker to improve treatment for patients.
Theres no such thing as a one-size-fits-all drug and increasingly scientists are developing ways to identify groups of patients that are most likely to respond to a particular drug. This approach is called stratified medicine and many scientists now believe it could transform cancer treatment in the future.
Provided by Newcastle University
- New test for ovarian cancer patients Nov 09, 2010 | not rated yet | 0
- New bowel cancer gene discovery Nov 10, 2010 | not rated yet | 0
- Guardian of genome predicts treatment outcomes for childhood cancer Nov 05, 2007 | not rated yet | 0
- Genetic 'hotspots' flag up opportunities for more personalised bowel cancer treatment Feb 10, 2010 | not rated yet | 0
- Anti-cancer gene: not what it was thought May 21, 2007 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer 21 hours ago | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer 21 hours ago | 5 / 5 (1) | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer May 24, 2013 | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer May 24, 2013 | 5 / 5 (2) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer May 24, 2013 | 5 / 5 (4) | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
2 hours ago | not rated yet | 4
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
2 hours ago | not rated yet | 1
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
21 hours ago | 3.7 / 5 (3) | 2 |
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
2 hours ago | not rated yet | 0
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
2 hours ago | not rated yet | 0
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
18 hours ago | 3 / 5 (2) | 0 |